ELS - VHD and Transcatheter Aortic Valve Replacement

Valvular Heart Disease - Aortic Stenosis

ACCF Transcatheter Aortic Valve Replacement GUIDELINES App brought to you free of charge courtesy of Guideline Central. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/396184

Contents of this Issue

Navigation

Page 3 of 11

Table 5. Risk Assessment Combining STS Risk Estimate, Frailty, Major Organ System Dysfunction, and Procedure- Specific Impediments Low Risk (Must Meet ALL Criteria in is Column) Intermediate Risk (Any 1 Criterion in is Column) High Risk (Any 1 Criterion in is Column) Prohibitive Risk (Any 1 Criterion in is Column) STS PROM a <4% AND 4%-8% OR >8% OR Predicted risk with surgery of death or major morbidity (all-cause) OR Frailty b None AND 1 index (mild) OR ≥2 indices (moderate to severe) OR >50% at 1 y OR Major organ system compromise not to be improved postoperatively c None AND 1 organ system OR No more than 2 organ systems OR ≥3 organ systems OR Procedure- specific impediment d None Possible procedure-specific impediment Possible procedure-specific impediment Severe procedure- specific impediment a Use of the STS PROM to predict risk in a given institution with reasonable reliability is appropriate only if institutional outcomes are within 1 standard deviation of STS average observed/expected ratio for the procedure in question. b Seven frailty indices: Katz Activities of Daily Living (independence in feeding, bathing, dressing, transferring, toileting, and urinary continence) and independence in ambulation (no walking aid or assist required or 5-meter walk in <6 s). Other scoring systems can be applied to calculate no, mild-, or moderate-to-severe frailty. c Examples of major organ system compromise: Cardiac—severe LV systolic or diastolic dysfunction or RV dysfunction, fixed PHTN; CKD stage 3 or worse; pulmonary dysfunction with FEV1 <50% or DLCO 2 <50% of predicted; CNS dysfunction (dementia, Alzheimer's disease, Parkinson's disease, stroke with persistent physical limitation); GI dysfunction—Crohn's disease, ulcerative colitis, nutritional impairment, or serum albumin <3.0; cancer—active malignancy; and liver—any history of cirrhosis, variceal bleeding, or elevated INR in the absence of VKA therapy. d Examples: tracheostomy present, heavily calcified ascending aorta, chest malformation, arterial coronary gra adherent to posterior chest wall, or radiation damage. Table 4. Stages of Progression of VHD Stage Definition Description A At risk Patients with risk factors for development of VHD B Progressive Patients with progressive VHD (mild-to-moderate severity and asymptomatic) C Asymptomatic severe Asymptomatic patients who meet the criteria for severe VHD: C1: Asymptomatic patients with severe VHD in whom the le or right ventricle remains compensated C2: Asymptomatic patients with severe VHD, with decompensation of the le or right ventricle D Symptomatic severe Patients who have developed symptoms as a result of VHD Evaluation

Articles in this issue

Archives of this issue

view archives of ELS - VHD and Transcatheter Aortic Valve Replacement - Valvular Heart Disease - Aortic Stenosis